

A Review on HPLC Method Development and Validation in Forced Degradation Studies

Putta Vaishnavi¹, Dr. R.Prasanthi¹, Dr. T. Mamatha^{1*}

Sarojini Naidu Vanita Pharmacy Mahavidyalaya, Tarnaka, Hyderabad, Telangana, India

tmamathasnvpmv@gmail.com

* Corresponding Author: Dr. T. Mamatha, Professor,

Abstract: *In the pharmaceutical sector, High-Performance Liquid Chromatography (HPLC) has emerged as a vital analytical method for both qualitative and quantitative assessment of medicinal ingredients and products. Because they shed light on the intrinsic stability of molecules and their degradation processes, forced degradation investigations are crucial to the development of stability-indicating methods. The methods used in HPLC method development and validation, as well as the importance of forced degradation studies in accordance with ICH principles, are the main topics of this paper. Crucial elements such mobile phase selection, column type, detection wavelength, system suitability, and robustness are highlighted, as are the difficulties and regulatory viewpoints associated with carrying out degradation studies..*

Keywords: Forced degradation study, Method Development, Validation, HPLC

I. INTRODUCTION

High- Performance Liquid Chromatography (HPLC) is a extensively used logical fashion in pharmaceutical analysis due to its high resolution, perceptivity, and perfection, making it essential for relating, quantifying, and separating active pharmaceutical constituents (APIs), excipients, and declination products [1, 2]. A robust HPLC system is pivotal for icing medicine safety, efficacy, and nonsupervisory compliance, especially in stability studies where stability-indicating styles are developed to distinguish APIs from their implicit declination products. Forced declination studies, or stress testing, play a crucial part in developing these styles by subjugating medicine substances to harsh conditions similar as acidic, introductory, oxidative, thermal, and photolytic surroundings to estimate their chemical stability and declination pathways. As per ICH guidelines Q1A (R2) and Q2 (R1), these studies are needed to support nonsupervisory cessions, understand molecular stability, and insure logical particularity. The data attained not only aids in system development and confirmation but also supports the design of further stable phrasings and packaging, buttressing the overall quality of pharmaceutical products. [3, 4]

PRINCIPLE

High-Performance Liquid Chromatography (HPLC) is a powerful and efficient analytical technique widely used for the separation, identification, and quantification of components in complex mixtures, particularly in pharmaceutical analysis. It works on the basis of analyte differential partitioning between a mobile phase (a liquid solvent or solvent combination) and a stationary phase (usually a solid or liquid supported on a solid matrix). Under high pressure, the mobile phase transports the analyte mixture along a column filled with the stationary phase, enabling separation according to the different affinities of the analytes for each phase. Stronger interactions with the stationary phase result in longer retention times, whereas compounds that are more soluble in the mobile phase elute faster. [4, 5]

TYPES OF HPLC

a) Normal Phase HPLC (NP-HPLC)

The mobile phase in NP-HPLC is non-polar (such as hexane or chloroform) whereas the stationary phase is polar (such as silica). Polarity is the basis for separation; less polar substances elute more quickly. This kind is especially helpful



for isolating geometric isomers or evaluating hydrophobic substances. However, it is less frequently utilized in standard pharmaceutical analysis because of its low repeatability and susceptibility to moisture. [6]

b) Reverse Phase HPLC (RP-HPLC)

The most popular method for pharmaceutical analysis is RP-HPLC. It uses a polar mobile phase (usually water combined with organic solvents like acetonitrile or methanol) and a non-polar stationary phase (usually C18-bonded silica). Polar molecules elute first in this mode, whereas non-polar compounds retain information for longer. RP-HPLC's high repeatability, compatibility with aqueous systems, and ease of method development make it perfect for the analysis of biological samples, degradation products, excipients, and API. [7]

c) Ion Exchange Chromatography

This technique separates ionic species according to their charge and affinity using a charged stationary phase. It is helpful for analyzing charged compounds such as proteins, nucleotides, peptides, and amino acids. The method is frequently used in formulations with ionic components and biopharmaceuticals.

d) Size Exclusion Chromatography (SEC)

SEC, also referred to as gel permeation chromatography, separates molecules according to their molecular weight and size. Because they are unable to pass through the stationary phase's pores, larger molecules elute more quickly, whereas smaller molecules elute later. SEC is widely used to assess molecular weight distribution and aggregation in proteins, polymers, and biopharmaceuticals. [8]

METHOD DEVELOPMENT IN HPLC

HPLC method development is a critical process in ensuring the effective separation and accurate quantification of analytes in pharmaceutical formulations. It involves optimizing several key parameters to achieve the desired resolution, sensitivity, and reproducibility. Below are the main factors involved in HPLC method development:

Selection of Mobile Phase

The mobile phase must be carefully selected to achieve good separation and peak shape. Acetonitrile, methanol, and water are examples of common solvents. Analyte ionization and retention are influenced by the mobile phase's pH. Peak shifting is avoided and a steady pH is maintained with the use of buffers. The retention time and resolution are influenced by the solvents' polarity and ratio. [9]

Column Selection

The most common use of C18 columns is because of their vast range of applications in reverse-phase HPLC. Particle size, internal diameter, and column length all affect separation effectiveness. Longer columns enhance resolution, whereas shorter ones cut down on analysis time. Although they improve separation, smaller particles raise backpressure. Analyte properties can be used to determine the column chemistry (e.g., C8, phenyl).

Detection and Wavelength Selection

UV detection is commonly used for its simplicity and sensitivity. The wavelength is selected based on the analyte's maximum absorbance (λ_{max}). Proper wavelength selection ensures optimal detection and accuracy. If the analyte lacks UV absorbance, alternate detectors like fluorescence or RI can be used. Dual or multi-wavelength detection helps monitor multiple compounds simultaneously.

Flow Rate and Temperature

Flow rate impacts analysis time, resolution, and column pressure. A typical flow rate ranges from 0.8–1.5 mL/min in standard HPLC. Temperature control (usually 25–40°C) enhances reproducibility and peak sharpness. Higher temperatures may reduce viscosity and improve flow but can degrade sensitive analytes. Both parameters are optimized for best performance and reproducibility. [10]

FORCED DEGRADATION STUDIES

Purpose

Stability tests that assist guarantee a drug's safety and effectiveness over its shelf life must include forced degradation experiments, commonly referred to as stress testing. These studies fulfill several important functions:



To determine degradation pathways: Knowing how and when a medicine degrades aids in forecasting how it will behave throughout production, storage, and use.

To illustrate stability-indicating capability: These investigations support the analytical method's (usually HPLC) capacity to reliably separate the medication from its breakdown products, demonstrating the method's stability-indicating nature.

To ascertain shelf-life and storage conditions: Proper packaging and storage guidelines, as well as an appropriate expiration date, can be developed by understanding how a medicine degrades under different stress circumstances.

To support regulatory submissions: To make sure a product is safe and effective for the duration of its stated shelf life, regulatory agencies like the FDA and EMA need proof from forced degradation tests.

To facilitate formulation and process development: Understanding degradation behavior aids in the creation of stronger manufacturing procedures and more stable medication compositions. [11]

Types of Stress Conditions (as per ICH Q1A(R2))

The purpose of forced degradation is to simulate potential degradation processes that could arise during the product lifespan by subjecting it to a variety of stress settings. Standard stress conditions are as follows, under ICH Q1A(R2) guidelines:

Acid hydrolysis: This method evaluates a drug's durability in low pH situations by subjecting it to acidic conditions, usually 0.1N HCL. This aids in assessing how the medication behaves in conditions similar to those in the stomach or when it is being broken down by acid.

Basic hydrolysis: Drugs that are hydrolytically sensitive or made with basic excipients benefit greatly from exposure to basic conditions, such as 0.1N NaOH, which mimic alkaline surroundings.

Oxidative degradation: Assesses the drug's vulnerability to oxidative stress using oxidizing agents such as hydrogen peroxide (typically 3%) of the mixture. This is crucial for medications that have functional groups like phenols, amines, or sulfides that are readily oxidizable.

Thermal deterioration: This method simulates heat-induced degradation that could happen during processing, storage, or transportation by subjecting the medication to high temperatures (such as 40–80°C).

Photolytic degradation: To test for photostability, drug compounds and goods are subjected to visible and ultraviolet light. This detects light-induced deterioration, which is important for medications kept in clear containers. [12]

Method Validation (ICH Q2(R1))

Method validation is a critical step in analytical method development, ensuring that the method is suitable for its intended use and meets regulatory standards. According to ICH Q2 (R1) guidelines, several parameters must be evaluated during method validation for pharmaceutical analysis, especially for stability-indicating HPLC methods.

Specificity

Measurement of the analyte response in the presence of possible interferences, such as contaminants, degradation products, excipients, or matrix components, is known as specificity.

Even in intricate formulations, it guarantees precise active pharmaceutical ingredient (API) identification and measurement.

Forced degradation studies demonstrate the specificity of stability-indicating methods, demonstrating that the approach is capable of separating and detecting all degradation products that are unique from the API.

Specificity claims can be supported by a peak purity study performed using a photodiode array (PDA) detector.

Linearity

The capacity of the method to yield findings that are exactly proportionate to the analyte concentration within a certain range is known as linearity.

In order to evaluate a linear connection, standard solutions at various concentration levels are usually analyzed in five to seven replicates.

The correlation coefficient (r^2) values for the majority of pharmaceutical applications should be ≥ 0.999 , and the findings are shown as a calibration curve.

The method's ability to consistently quantify analytes across a wide concentration range is ensured by linearity.



Accuracy and Precision

Accuracy: The degree to which measured quantities resemble the true or recognized value is known as accuracy. Recovery studies, in which known quantities of analyte are inserted into the matrix and subsequently assessed, are typically used to test it.

Precision: Precision evaluates the method's repeatability under typical circumstances. Repeatability (intra-day precision) refers to testing conducted by the same analyst on the same day.

Inter-day precision, often known as intermediate precision, refers to testing conducted by various analysts or instruments on separate days.

For good precision, the relative standard deviation, or RSD, should normally be less than 2%. [13]

Limit of Detection (LOD) and Limit of Quantification (LOQ)

LOD, which is commonly assessed using a signal-to-noise ratio of 3:1, is the lowest concentration of an analyte that can be detected but not always measured.

The limit of quantification (LOQ), which is usually based on a signal-to-noise ratio of 10:1, is the lowest concentration that can be ascertained quantitatively with reasonable precision and accuracy.

These limits are crucial for trace-level detection in stability investigations and impurity profiling.

Robustness

Robustness assesses how reliable the procedure is under minor, intentional changes in the analytical environment.

It examines the effects of variables such as the composition of the mobile phase, flow rate, pH, column temperature, and detection wavelength.

A robust technique displays consistent performance despite slight operational variations, ensuring real-world application.

Although it is frequently carried out later in the research process, this phase is crucial for technique transferability between labs. [13-14]

II. CONCLUSION

Pharmaceutical stability analysis depends on the development and validation of HPLC methods as well as forced degradation studies to guarantee that medications are safe, efficacious, and of good quality for the duration of their shelf lives. As advised by ICH recommendations, these investigations make it possible to identify and measure the active medicinal substances and the byproducts of their breakdown under varied stress situations. The specificity, accuracy, precision, and robustness of a well-developed and validated stability-indicating HPLC technique make it appropriate for routine quality control and regulatory submissions. Optimizing formulations, packaging, and storage conditions is made easier when one is aware of a drug's degrading tendency. All things considered, these analytical procedures are essential to maintaining drug purity and fulfilling strict legal obligations.

REFERENCES

- [1]. International Conference on Harmonisation (ICH) Q1A(R2). Stability Testing of New Drug Substances and Products. ICH Harmonised Tripartite Guideline, 2003.
- [2]. International Conference on Harmonisation (ICH) Q2(R1). Validation of Analytical Procedures: Text and Methodology. ICH Harmonised Tripartite Guideline, 2005.
- [3]. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability-indicating studies of drugs—A review. *Journal of Pharmaceutical Analysis*. 2014; 4(3):159–165. <https://doi.org/10.1016/j.jpha.2013.09.003>
- [4]. Bakshi M, Singh S. Development of validated stability-indicating assay methods—critical review. *Journal of Pharmaceutical and Biomedical Analysis*. 2002; 28(6):1011–1040. [https://doi.org/10.1016/S0731-7085\(02\)00047-X](https://doi.org/10.1016/S0731-7085(02)00047-X)
- [5]. Snyder LR, Kirkland JJ, Dolan JW. *Introduction to Modern Liquid Chromatography*. 3rd ed. Wiley-Interscience; 2010.



- [6]. Sethi PD. HPLC: High Performance Liquid Chromatography – Quantitative Analysis of Pharmaceutical Formulations. CBS Publishers; 2001.
- [7]. United States Pharmacopeia (USP) General Chapter <621>: Chromatography. United States Pharmacopeial Convention.
- [8]. Singh S, Bakshi M. Guidance on conducting forced degradation studies. Pharmaceutical Technology. 2000;24(2):1–14.
- [9]. Kazakevich Y, Lofrutto R. HPLC for Pharmaceutical Scientists. Wiley-Interscience; 2007.
- [10]. Meyer VR. Practical High-Performance Liquid Chromatography. 5th ed. Wiley; 2010.
- [11]. FDA. Guidance for Industry: Analytical Procedures and Methods Validation for Drugs and Biologics. U.S. Department of Health and Human Services, Food and Drug Administration, 2015.
<https://www.fda.gov/media/87801/download>
- [12]. European Medicines Agency (EMA). ICH Guideline Q3B(R2): Impurities in New Drug Products, 2006.
- [13]. Kumar A, Nair AG, Reddy AV. A review on stability indicating HPLC method development. World Journal of Pharmaceutical Research. 2016;5(12):1481–1495.
(Explains practical steps for developing stability-indicating methods using HPLC)
- [14]. Alsante KM, Ando A, Brown R, Ensing J, Hatajik TD, Kong W, Tsuda Y. The role of degradant profiling in active pharmaceutical ingredients and drug products. Advanced Drug Delivery Reviews. 2007;59(1):29–37.
<https://doi.org/10.1016/j.addr.2006.10.003>

